论文部分内容阅读
目的:建立分子靶向药物索拉菲尼(Sorafenib)临床治疗肝细胞癌(HCC)敏感性的新型预测方法。方法:将HCC手术切除癌症标本外围组织性状较好的部分处理成1 mm~3,原位接种于免疫缺陷的BALB/c小鼠肝脏,4~6周后B超检测其生长状况;当肿瘤长至2~3 mm~3时,用生理盐水配置Sorafenib溶液,以2 mg/kg用量对小鼠进行隔日口服灌胃给药,共给药10次。最后收集动物,观察肝脏原位肿瘤的大小,同时进行病理检测,考察Sorafenib的抗肿瘤治疗效果。结果:实验动物肝脏拍照和病理结果均显示,与溶剂对照组相比,Sorafenib治疗组小鼠肝脏原位HCC病灶明显缩小或消除。结论:建立了HCC分子靶向治疗临床药敏检测方法,为临床有效且个体化治疗HCC提供了新途径。
Objective: To establish a new prediction method for the sensitivity of molecular targeted drug Sorafenib in the treatment of hepatocellular carcinoma (HCC). Methods: The histopathological sections of HCC surgically resected from 1 to 3 weeks were inoculated into the immunocompromised BALB / c mouse liver. After 4 to 6 weeks, the growth of the tumor was examined by ultrasonography. When the tumors When grown to 2 ~ 3 mm ~ 3, Sorafenib solution was administered with normal saline, and mice were orally administered orally by 2 mg / kg for 10 times. Finally, the animals were collected to observe the size of liver tumor in situ, at the same time for pathological examination to investigate the antitumor effect of Sorafenib. Results: The liver photographs and pathological results of experimental animals showed that compared with the solvent control group, the in situ HCC lesions of mice in the Sorafenib treatment group were significantly reduced or eliminated. CONCLUSION: A clinical drug sensitivity test for molecular targeted therapy of HCC has been established, which provides a new approach for the clinical treatment of HCC with individualized treatment.